Table 2 Cost-effectiveness results for the base-case analysis
StrategyMean costs (£)Mean QALYsICER (£)Probability of being cost-effective for threshold at:
£20 000£30 000
Lifetime analysis
CHADS2  =  0RFCA25 24012.3777630.9830.996
AADs14 41510.98
CHADS2  =  1RFCA26 02712.1477800.9810.996
AADs15 36710.77
CHADS2  =  2RFCA26 98711.8777650.9860.999
AADs16 51710.52
CHADS2  =  3RFCA28 34311.4979100.9921.000
AADs18 10710.19
5-year analysis
CHADS2  =  0RFCA25 25111.3527 7450.0910.577
AADs14 42910.96
CHADS2  =  1RFCA26 01611.1825 5100.1650.686
AADs15 35210.76
CHADS2  =  2RFCA26 97210.9723 2020.2650.786
AADs16 49910.52
CHADS2  =  3RFCA28 36610.6720 8310.4180.881
AADs18 13310.18
  • AAD, anti-arrhythmic drug; CHADS2, congestive heart failure, hypertension, age 75, diabetes mellitus, and prior stroke; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; RFCA, radiofrequency catheter ablation.